DOCKET NO.: JJPR-0043 PATENT

Application No.: 10/727,021

Office Action Dated: June 13, 2006

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1-23. (Canceled)

24. (Currently amended) A method for isolating a nucleic acid molecule encoding a

homologue of human histamine H3 receptor comprising the steps of:

(a) mixing a nucleic acid molecule comprising a nucleotide sequence encoding

human histamine H3 receptor comprising the amino acid sequence of SEQ ID NO:7 with a

sample comprising a nucleic acid molecule encoding a homologue of human histamine H3

receptor;

(b) allowing said nucleic acid molecule comprising a nucleotide sequence

encoding human histamine H3 receptor to hybridize with said nucleic acid molecule encoding

a homologue of human histamine H3 receptor to form a hybridized nucleic acid complex;

(c) isolating the hybridized nucleic acid complex; and

(d) purifying the nucleic acid molecule encoding a human histamine H3 receptor

homologue,

wherein said histamine H3 receptor homologue comprises biological activity of

human histamine H3 receptor comprising the amino acid sequence of SEQ ID NO:7, wherein

said biological activity comprises is selected from binding to a histamine H3 receptor-specific

ligand, cyclic AMP induction in the presence of a histamine H3 receptor antagonist,

inhibition of adenylate cyclase in response to histamine, or incorporation of GTP-gamma-S.

25. (Previously Presented) The method according to claim 24 wherein said

nucleic acid molecule comprising a nucleotide sequence encoding human histamine H3

receptor comprises the nucleotide sequence of SEQ ID NO:5 or SEQ ID NO:6.

Page 3 of 8

DOCKET NO.: JJPR-0043 **PATENT**

Application No.: 10/727,021

Office Action Dated: June 13, 2006

26. (Canceled)

27. (Currently amended) A method for producing a homologue of human

histamine H3 receptor comprising the steps of:

mixing a nucleic acid molecule comprising a nucleotide sequence encoding (a)

human histamine H3 receptor comprising the amino acid sequence of SEQ ID NO:7 with a

sample comprising a nucleic acid molecule encoding a homologue of human histamine H3

receptor;

(b) allowing said nucleic acid molecule comprising a nucleotide sequence

encoding human histamine H3 receptor to hybridize with said nucleic acid molecule encoding

a homologue of human histamine H3 receptor to form a hybridized nucleic acid complex;

isolating the hybridized nucleic acid complex; and (c)

(d) purifying the nucleic acid molecule encoding a human histamine H3 receptor

homologue; and

(e) recombinantly expressing said nucleic acid molecule encoding a human

histamine H3 receptor homologue,

thereby producing said human histamine H3 receptor homologue, wherein said

histamine H3 receptor homologue comprises biological activity of a human histamine H3

receptor comprising the amino acid sequence of SEQ ID NO:7, wherein said biological

activity comprises is selected from binding to a histamine H3 receptor-specific ligand, cyclic

AMP induction in the presence of a histamine H3 receptor antagonist, inhibition of adenylate

cyclase in response to histamine, or incorporation of GTP-gamma-S.

Page 4 of 8

DOCKET NO.: JJPR-0043 PATENT

Application No.: 10/727,021

Office Action Dated: June 13, 2006

28. (Previously Presented) The method according to claim 27 wherein said nucleic acid molecule comprising a nucleotide sequence encoding human histamine H3 receptor comprises the nucleotide sequence of SEQ ID NO:5 or SEQ ID NO:6.

29-33. (Canceled)

- 34. (Previously Presented) The method according to claim 27 wherein said homologue has a greater affinity for a ligand than the polypeptide having the amino acid sequence of SEQ ID NO:7, wherein said ligand is histamine or methylhistamine.
- 35. (Previously Presented) The method according to claim 27 wherein said homologue has a reduced affinity for a ligand than the polypeptide having the amino acid sequence of SEQ ID NO:7, wherein said ligand is histamine or methylhistamine.

36-37. (Canceled)

- 38. (Currently amended) A method for detecting the presence of a nucleic acid molecule encoding a human histamine H3 receptor in a sample comprising nucleic acid molecules, said method comprising the steps of:
- (a) mixing said sample with a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:5, the nucleotide sequence of SEQ ID NO:6, the nucleotide sequence of SEQ ID NO:8, or the nucleotide sequence encoding SEQ ID NO:7; and
- (b) detecting hybridization of said nucleic acid molecule to a nucleic acid molecule in said sample,

wherein said nucleic acid molecule encoding a human histamine H3 receptor comprises biological activity of a human histamine H3 receptor comprising the amino acid sequence of SEQ ID NO:7, wherein said biological activity comprises is selected from binding to a histamine H3 receptor-specific ligand, cyclic AMP induction in the presence of a

DOCKET NO.: JJPR-0043 PATENT

Application No.: 10/727,021

Office Action Dated: June 13, 2006

histamine H3 receptor antagonist, inhibition of adenylate cyclase in response to histamine, or

incorporation of GTP-gamma-S.

39-54. (Canceled)

55. (Previously Presented) The method of claim 24 wherein said histamine H3

receptor-specific ligand comprises histamine or methylhistamine.

56. (Previously Presented) The method of claim 27 wherein said histamine H3

receptor-specific ligand comprises histamine or methylhistamine.

57. (Previously Presented) The method of claim 38 wherein said histamine H3

receptor-specific ligand comprises histamine or methylhistamine.

58. (Canceled)

59. (Canceled)

60. (Previously Presented) The method of claim 24 wherein said histamine H3

receptor antagonist comprises thioperamide.

61. (Previously Presented) The method of claim 27 wherein said histamine H3

receptor antagonist comprises thioperamide.

62. (Previously Presented) The method of claim 38 wherein said histamine H3

receptor antagonist comprises thioperamide.

63. (Canceled)

Page 6 of 8